NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
20 trialsNCT07419464 2026-04-09
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
NCT01693718 2024-01-29
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
University of Chicago
Phase 2 Completed
NCT01172470 2023-11-29
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
University of Chicago
Phase 2 Completed
NCT01185158 2023-11-29
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
University of Chicago
Phase 2 Completed
NCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT03737968 2023-03-21
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Yonsei University
Phase 2 Unknown
NCT02126969 2023-03-13
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
University of Kentucky
Phase 2 Completed
NCT01884259 2022-05-26
HNO-2
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT01326923 2020-10-09
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 2 Terminated
NCT02540928 2018-07-18
AMG 319 in HPV Positive and Negative HNSCC
Cancer Research UK
Phase 2 Terminated
NCT01287390 2016-01-27
Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck
University Hospital, Ghent
Phase 2 Completed
NCT01087970 2014-05-19
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00589667 2014-04-02
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01427205 2013-04-05
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00100789 2012-10-01
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Completed